Literature DB >> 20587194

Cryptococcus gattii genotype VGIIa infection in man, Japan, 2007.

Koh Okamoto1, Shuji Hatakeyama, Satoru Itoyama, Yoko Nukui, Yusuke Yoshino, Takatoshi Kitazawa, Hiroshi Yotsuyanagi, Reiko Ikeda, Takashi Sugita, Kazuhiko Koike.   

Abstract

We report a patient in Japan infected with Cryptococcus gattii genotype VGIIa who had no recent history of travel to disease-endemic areas. This strain was identical to the Vancouver Island outbreak strain R265. Our results suggest that this virulent strain has spread to regions outside North America.

Entities:  

Mesh:

Year:  2010        PMID: 20587194      PMCID: PMC3321916          DOI: 10.3201/eid1607.100106

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Cryptococcus neoformans and C. gattii are closely related species of yeast; C. gattii was previously classified as C. neoformans var. gattii (). Although both species cause pulmonary or central nervous system infections, they differ in their ecology, epidemiology, and pathobiology. C. neoformans is the most common Cryptococcus spp. worldwide and mainly affects immunocompromised hosts. In contrast, C. gattii mainly affects immunocompetent hosts and often forms mass-like lesions (cryptococcomas). Multilocus sequence typing can be used to divide this species into 4 molecular genotypes, VGI–VGIV, which differ in epidemiology and virulence (,). C. gattii was believed to be restricted to tropical and subtropical areas such as Australia, Southeast Asia, and South America (). However, in 1999, a C. gattii infection outbreak occurred on Vancouver Island, British Columbia, Canada (), which has a temperate climate. During the Vancouver Island outbreak, most human, animal, and environmental isolates obtained belonged to VGIIa (major genotype, 90%–95% of isolates) and VGIIb (minor genotype, 5%–10% of isolates) (,). These strains have now spread to mainland British Columbia and the Pacific Northwest region of the United States (,,). The potential for further spread of this strain, particularly the VGIIa genotype, is a serious concern because it is highly virulent in mammals and can infect immunocompetent persons (). We report a case of cerebral cryptococcoma caused by C. gattii VGIIa (a strain identical to the Vancouver Island outbreak major genotype strain R265) in a patient from Japan who had no recent travel history to known disease-endemic areas.

The Patient

In 2007, a 44-year-old man (sign painter) from Japan who was not infected with HIV came to the University of Tokyo Hospital with a 2-month history of headache and loss of right-sided vision in both eyes (right homonymous hemianopsia). He had had a diagnosis of hyperglycemia 3 years before admission but had declined to seek medical treatment. His medical history was otherwise unremarkable. He was an ex-smoker who rarely consumed alcohol and was not taking any prescription medications (including corticosteroids or other immunosuppressive drugs). He had traveled to Guam in 1990 and Saipan in 1999 and had no other history of overseas travel. He reported exposure to his dog, and he did not spend time in wilderness areas. The patient often worked near construction sites in urban locations. When hospitalized, the patient was afebrile and had stable vital signs. Physical examination showed agraphia (inability to write), anarithmia (inability to count numbers), right homonymous hemianopsia, and Romberg sign. Laboratory evaluations showed increased glucose (367 mg/dL) and hemoglobin A1c (10.5%) levels. Results of a complete blood cell count and hepatic and renal function tests were within normal limits. Levels of electrolytes and C-reactive protein were also within normal limits. Results of a test for antibodies to HIV-1/2 were negative. An enhanced brain magnetic resonance imaging scan showed a 4.4 × 4.1 × 3.3–cm lobulated mass in the left occipital lobe with surrounding edema. The lesion had low signal intensity on T1-weighted images, moderate signal intensity on T2-weighted images, and rim enhancement on T1-weighted images after administration of gadolinium (Figure). A chest computed tomography scan showed a 1.8 × 1.2–cm nodule in the left lower lung (S8 segment).
Figure

Postcontrast T1-weighted magnetic resononance image of the brain of a 44-year-old man with cerebral cryptococomma in Japan, 2007, showing a rim-enhancing lobulated mass (lower right) with surrounding edema in the left occipital lobe.

Postcontrast T1-weighted magnetic resononance image of the brain of a 44-year-old man with cerebral cryptococomma in Japan, 2007, showing a rim-enhancing lobulated mass (lower right) with surrounding edema in the left occipital lobe. The brain mass was completely resected because it was suspected to be a tumor. Pathologic evaluation of the resected specimen showed that the mass was a large abscess containing encapsulated yeast. The yeast could be seen after staining with periodic acid–Schiff and Grocott methenamine silver stains. Specimen cultures were positive for Cryptococcus spp. and led to a diagnosis of cerebral cryptococcosis. The patient was treated with liposomal amphotericin B (4 mg/kg/d for 3 weeks) and flucytosine (100 mg/kg/d for 3 weeks). A cerebrospinal fluid (CSF) sample obtained by lumbar puncture soon after mass resection showed a slightly increased protein level but no leukocytosis or a low glucose concentration. Fungal cultures of the CSF showed negative results. Cryptococcal antigen titers were >512 in serum and 64 in CSF. After 3 weeks of induction therapy, the patient received consolidation and maintenance therapy (oral fluconazole, 400 mg/d) for 1 year. The pulmonary nodule decreased in size after antifungal treatment, suggesting that this lesion was a pulmonary cryptococcoma. At the 1-year follow-up visit, the cerebral cryptococcoma had not recurred, and the pulmonary nodule had disappeared. The cryptococcal strain isolated from the brain was identified as serotype B by slide agglutination test () and identified as C. gattii by rRNA gene sequence analysis (). Eleven unlinked loci (SXI1, IGS, TEF1, GPD1, LAC1, CAP10, PLB1, MPD1, HOG1, BWC1, and TOR1) analyzed by multilocus sequence typing, according to the method of Fraser et al. (), were identical to those of the Vancouver Island major genotype strain R265 (genotype VGIIa) (Table) (,,). MICs of this isolate were 0.125, 0.5, 1.0, and 0.011 µg/mL for amphotericin B, flucytosine, fluconazole, and itraconazole, respectively.
Table

Multilocus sequence typing profiles of 2 Cryptococcus gattii strains, Japan, 2007*

StrainMultilocus sequence typing profile†
SXI1α IGS TEF1 GPD1 LAC1 CAP10 PLB1 MPD1 HOG1 BWC1 TOR1
JP01184714115111
R265184714115111

*JP01, strain from Japan (patient in this study); R265, Vancouver Island genotype VGIIa strain.
†GenBank accession nos. for multilocus sequencing typing alleles: SXI1α_18, DQ096308; IGS_4, DQ096314; TEF1_7, DQ096364; GPD1_1, DQ096377; LAC1_4, DQ096400; CAP10_1, DQ096416; PLB1_1, DQ096343; MPD1_5, DQ096334; HOG1_1, DQ096456; BWC1_1, DQ096428; TOR1_1, DQ096470.

*JP01, strain from Japan (patient in this study); R265, Vancouver Island genotype VGIIa strain.
†GenBank accession nos. for multilocus sequencing typing alleles: SXI1α_18, DQ096308; IGS_4, DQ096314; TEF1_7, DQ096364; GPD1_1, DQ096377; LAC1_4, DQ096400; CAP10_1, DQ096416; PLB1_1, DQ096343; MPD1_5, DQ096334; HOG1_1, DQ096456; BWC1_1, DQ096428; TOR1_1, DQ096470.

Conclusions

Japan has not been considered a C. gattii–endemic area. There have been only 2 reports of C. gattii infections in Japan; both infections apparently originated in Australia (,). Retrospective surveillance studies found no evidence of C. gattii infection or colonization in Japan (; Ministry of Health, Labor and Welfare of Japan, 2003, unpub. data). Although the source of the infection in the patient reported here has not been identified, it appears to have originated in Japan. Infections with C. gattii have not been reported in the places the patient had visited (Guam and Saipan) (,). Analysis of persons who traveled to Vancouver Island indicated that the median incubation period of C. gattii infection is 6–7 months (range 2–11 months) (), although an incubation period of 13 months has been reported for 1 patient (). C. gattii genotype VGIIa may have been present in the Pacific Northwest region of the United States long before the Vancouver Island outbreak (,). However, no human cases were identified in the United States until January 2006 (,). Genotype VGIIa has now spread from Vancouver Island to mainland British Columbia and the Pacific Northwest region of the United States, possibly because of human activity or animal migration (). However, this genotype has not been reported in any other region, although similar isolates have been obtained from South America () and from patients who had traveled to affected areas (,). Thus, our findings indicate possible global dispersal of this strain. Our results suggest that C. gattii VGIIa genotype may be spreading. In North America, this genotype has been isolated from various environmental specimens such as tree surfaces, soil, water, and air (,). Soil is believed to be a major potential reservoir of this organism (,). Thus, ecologic and environmental studies on C. gattii in Japan are needed to determine likely reservoirs and to improve understanding of C. gattii epidemiology. Although many clinical laboratories in Japan currently do not differentiate between C. neoformans and C. gattii infections, identification of cryptococcal isolates to the species level, especially in apparently immunocompetent patients, is needed.
  15 in total

1.  Immunohistochemical diagnosis of Cryptococcus neoformans var. gattii infection in chronic meningoencephalitis: the first case in Japan.

Authors:  T Tsunemi; T Kamata; Y Fumimura; M Watanabe; M Yamawaki; Y Saito; T Kanda; K Ohashi; N Suegara; S Murayama; K Makimura; H Yamaguchi; H Mizusawa
Journal:  Intern Med       Date:  2001-12       Impact factor: 1.271

2.  Emergence of Cryptococcus gattii in a novel environment provides clues to its incubation period.

Authors:  L MacDougall; M Fyfe
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

3.  Diversity among strains of Cryptococcus neoformans var. gattii as revealed by a sequence analysis of multiple genes and a chemotype analysis of capsular polysaccharide.

Authors:  T Sugita; R Ikeda; T Shinoda
Journal:  Microbiol Immunol       Date:  2001       Impact factor: 1.955

4.  Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak.

Authors:  James A Fraser; Steven S Giles; Emily C Wenink; Scarlett G Geunes-Boyer; Jo Rae Wright; Stephanie Diezmann; Andria Allen; Jason E Stajich; Fred S Dietrich; John R Perfect; Joseph Heitman
Journal:  Nature       Date:  2005-10-09       Impact factor: 49.962

5.  Epidemiology studies of clinical isolates of Cryptococcus neoformans of Japan by restriction fragment length polymorphism.

Authors:  S Kohno; A Varma; K J Kwon-Chung; K Hara
Journal:  Kansenshogaku Zasshi       Date:  1994-12

6.  A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada).

Authors:  S E Kidd; F Hagen; R L Tscharke; M Huynh; K H Bartlett; M Fyfe; L Macdougall; T Boekhout; K J Kwon-Chung; W Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-30       Impact factor: 11.205

Review 7.  Spread of Cryptococcus gattii into Pacific Northwest region of the United States.

Authors:  Kausik Datta; Karen H Bartlett; Rebecca Baer; Edmond Byrnes; Eleni Galanis; Joseph Heitman; Linda Hoang; Mira J Leslie; Laura MacDougall; Shelley S Magill; Muhammad G Morshed; Kieren A Marr
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

8.  First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak.

Authors:  Arlo Upton; James A Fraser; Sarah E Kidd; Camille Bretz; Karen H Bartlett; Joseph Heitman; Kieren A Marr
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

9.  Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates.

Authors:  R Ikeda; T Shinoda; Y Fukazawa; L Kaufman
Journal:  J Clin Microbiol       Date:  1982-07       Impact factor: 5.948

10.  Cryptococcus gattii: An Emerging Cause of Fungal Disease in North America.

Authors:  Ashwin Dixit; Scott F Carroll; Salman T Qureshi
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-05-25
View more
  29 in total

1.  Cryptococcus gattii as an important fungal pathogen of western North America.

Authors:  Kieren A Marr
Journal:  Expert Rev Anti Infect Ther       Date:  2012-06       Impact factor: 5.091

2.  Macrolides Inhibit Capsule Formation of Highly Virulent Cryptococcus gattii and Promote Innate Immune Susceptibility.

Authors:  Shigeki Nakamura; Yurika Ikeda-Dantsuji; Lianjin Jin; Yoshitsugu Higashi; Masahiro Abe; Tatsuya Inukai; Minoru Nagi; Makoto Urai; Yoshitsugu Miyazaki
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Rare Cryptococus gattii infection in an immunocompetent dairy goat following a cesarean section.

Authors:  Aurora Villarroel; Tessa R Maggiulli
Journal:  Med Mycol Case Rep       Date:  2012-10-03

4.  Case Series: Report of the First Two Human Indigenous Cases of Cryptococcus gattii Infection in Eastern Canada.

Authors:  Jessica St-Pierre; Philippe J Dufresne; Alex Carignan; Émilie Lévesque; Francis Bernard; Jean Longtin; Louiselle LeBlanc
Journal:  Mycopathologia       Date:  2017-10-30       Impact factor: 2.574

Review 5.  Cryptococcus gattii Genotype VGIIa Infection in an Immunocompetent Japanese Patient: A Case Report and Mini-review.

Authors:  Makoto Nakao; Hideki Muramatsu; Tetsushi Takahashi; Shunsuke Niwa; Yusuke Kagawa; Ryota Kurokawa; Kazuki Sone; Yuki Uozumi; Misako Ohkusu; Katsuhiko Kamei; Hiroshi Koga
Journal:  Intern Med       Date:  2016-10-15       Impact factor: 1.271

6.  Clinical, epidemiological and outcome features of patients with cryptococcosis in Uberaba, Minas Gerais, Brazil.

Authors:  Delio José Mora; Eduardo Rodrigues da Cunha Colombo; Kennio Ferreira-Paim; Leonardo Eurípedes Andrade-Silva; Gabriel Antonio Nogueira Nascentes; Mario León Silva-Vergara
Journal:  Mycopathologia       Date:  2011-12-01       Impact factor: 2.574

Review 7.  Cryptococcus gattii infections.

Authors:  Sharon C-A Chen; Wieland Meyer; Tania C Sorrell
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 8.  Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals.

Authors:  Edmond J Byrnes; Karen H Bartlett; John R Perfect; Joseph Heitman
Journal:  Microbes Infect       Date:  2011-06-01       Impact factor: 2.700

9.  Cryptococcus gattii, no longer an accidental pathogen?

Authors:  Deborah J Springer; Sujal Phadke; Blake Billmyre; Joseph Heitman
Journal:  Curr Fungal Infect Rep       Date:  2012-12

Review 10.  Epidemiology of fungal infections in China.

Authors:  Min Chen; Yuan Xu; Nan Hong; Yali Yang; Wenzhi Lei; Lin Du; Jingjun Zhao; Xia Lei; Lin Xiong; Langqi Cai; Hui Xu; Weihua Pan; Wanqing Liao
Journal:  Front Med       Date:  2018-01-11       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.